Enovis Corporation (NYSE:ENOV) Receives $41.29 Consensus PT from Analysts

Enovis Corporation (NYSE:ENOV) has earned an average rating of “Moderate Buy” from the ten research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $41.2857.

A number of brokerages have issued reports on ENOV. BMO Capital Markets reaffirmed an “outperform” rating and set a $30.00 price target on shares of Enovis in a report on Friday, August 7th. Wells Fargo & Company cut their target price on Enovis from $40.00 to $39.00 and set an “overweight” rating on the stock in a research report on Friday, August 7th. Zacks Research upgraded Enovis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. Evercore set a $32.00 price target on Enovis in a report on Monday, July 6th. Finally, Wall Street Zen cut shares of Enovis from a “buy” rating to a “hold” rating in a report on Saturday, August 8th.

Insider Activity at Enovis

In related news, insider Oliver Engert bought 1,200 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The shares were purchased at an average cost of $21.62 per share, with a total value of $25,944.00. Following the transaction, the insider directly owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. This represents a 2.37% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders have acquired 4,200 shares of company stock valued at $92,084. Company insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Enovis

Several large investors have recently bought and sold shares of the stock. Rubric Capital Management LP purchased a new stake in shares of Enovis in the 3rd quarter valued at about $83,435,000. Paradigm Capital Management Inc. NY purchased a new position in Enovis during the 2nd quarter worth approximately $28,533,000. California State Teachers Retirement System grew its stake in Enovis by 1,635.6% during the 2nd quarter. California State Teachers Retirement System now owns 1,335,833 shares of the company’s stock worth $27,652,000 after buying an additional 1,258,867 shares during the last quarter. Bank of America Corp DE acquired a new position in Enovis during the second quarter worth approximately $11,502,000. Finally, AQR Capital Management LLC increased its position in Enovis by 682.6% during the second quarter. AQR Capital Management LLC now owns 498,317 shares of the company’s stock worth $15,627,000 after buying an additional 434,646 shares during the period. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Trading Down 3.5%

Shares of NYSE:ENOV opened at $25.15 on Tuesday. Enovis has a 52 week low of $19.14 and a 52 week high of $34.28. The company’s 50 day moving average is $25.31 and its two-hundred day moving average is $24.19. The company has a market cap of $1.45 billion, a PE ratio of -1.31 and a beta of 1.34. The company has a current ratio of 1.98, a quick ratio of 1.00 and a debt-to-equity ratio of 0.84.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.05. The business had revenue of $582.78 million during the quarter, compared to analysts’ expectations of $581.84 million. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The company’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.79 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities analysts predict that Enovis will post 3.15 earnings per share for the current fiscal year.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.